Brooklyn ImmunoTherapeutics, Inc. 是一家臨床階段的生物製藥公司,致力於開發治療癌症患者的療法。公司總部位於紐約布魯克林。
財務指標
營業收入
2024-09-30
$487K
2024-06-30
$47K
2024-03-31
$47K
2023-12-31
$17K
營業支出
2024-09-30
$2.8M
2024-06-30
$4.88M
2024-03-31
$5.23M
2023-12-31
$5.23M
淨利潤
2024-09-30
-$26.6M
2024-06-30
-$5.52M
2024-03-31
-$6.64M
2023-12-31
-$6.15M
淨利潤率
2024-09-30
-5.46K%
2024-06-30
-11.76K%
2024-03-31
-14.14K%
2023-12-31
-36.19K%
每股收益
2024-09-30
--
2024-06-30
--
2024-03-31
--
2023-12-31
--
息稅折舊攤銷前利潤
2024-09-30
-$24.45M
2024-06-30
-$4.15M
2024-03-31
-$5.31M
2023-12-31
-$5.28M
有效稅率
2024-09-30
-0.04%
2024-06-30
-0.05%
2024-03-31
-0.06%
2023-12-31
0.06%
項目
2024-09-30
2024-06-30
2024-03-31
2023-12-31
營業收入
$487K
$47K
$47K
$17K
營業支出
$2.8M
$4.88M
$5.23M
$5.23M
淨利潤
-$26.6M
-$5.52M
-$6.64M
-$6.15M
淨利潤率
-5.46K%
-11.76K%
-14.14K%
-36.19K%
每股收益
--
--
--
--
息稅折舊攤銷前利潤
-$24.45M
-$4.15M
-$5.31M
-$5.28M
有效稅率
-0.04%
-0.05%
-0.06%
0.06%
常見問題
BTX stock represents ownership shares in a publicly traded company. The ticker BTX is listed on a U.S. exchange, and the stock allows investors to participate in the company's financial performance. Because BTX may refer to different firms over time, the specific company, business model, and listing details should be confirmed using the latest profile data on the BTX stock page. That page provides the most current information about what BTX represents and how it operates.
The business operations behind BTX depend on the issuing company. BTX may be associated with biotechnology, pharmaceuticals, or another sector, so its products, services, and revenue sources are best verified through the company description on the BTX stock page. Reviewing that description helps investors understand the company's core activities, target markets, and competitive position without relying on assumptions about the ticker alone.
The 52-week range shows the lowest and highest prices at which BTX stock has traded over the past year. It gives context for where the current price sits relative to recent extremes. Because the range changes as new trading days occur, the exact figures for BTX should be checked in the latest price data displayed on the BTX stock page rather than estimated or assumed.
Useful valuation metrics for BTX can include the price-to-earnings ratio, price-to-sales ratio, price-to-book ratio, and enterprise value relative to EBITDA, depending on whether the company is profitable and how it is structured. Comparing BTX with peers in its industry and reviewing its own historical valuation can add context. The most current metric values should be taken from the BTX stock page.
BTX stock may be eligible for pre-market and after-hours trading through certain brokers, but extended-hours sessions typically have lower liquidity, wider spreads, and higher volatility than regular trading hours. Not all brokers support off-hours trading for every stock, and orders may execute at less favorable prices. Investors should check with their brokerage and review the BTX trading information on the page for any available session details.
Risks associated with BTX can include company-specific factors such as financial performance, competitive pressure, regulatory or legal developments, and dependence on key products or customers. Broader market, sector, interest rate, and economic risks may also affect the stock. The relative importance of these risks depends on the company behind BTX, so investors should review its latest disclosures and the risk information available on the BTX stock page.